Wenger Vieli advises Xeltis on securing EUR 15M in its Series D2 Financing Round

Wenger Vieli has acted as legal advisor to Xeltis, a clinical-stage company developing medical devices enabling cardiovascular restoration, on securing EUR 15 million in equity and license fees from the lead investor as cornerstone funding in its ongoing Series D2 financing round.

The round is led by Grand Pharmaceutical Group, a global comprehensive pharmaceutical enterprise based in the People’s Republic of China.

Xeltis is a Swiss/Dutch clinical-stage medical device company with registered seat in Eindhoven offering the most advanced polymer-based restorative devices for cardiovascular treatment.

The team was led by Beat Speck (partner, venture capital / m&a, pictured) and included Dominik Rietiker (associate, venture capital / m&a) and Andrea Christen (associate, notarial services).

Wenger Vieli advises Xeltis on securing  EUR 15M in its Series D2 Financing Round



Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).

For further information, please visit the Group’s website www.lcpublishinggroup.com

LC Publishing Group S.p.A. – Via Tolstoi 10 – 20146 Milano – Tel. 0236727659 – C.F./P.IVA 07619210961
REA 1971432 Registro delle Imprese di Milano – Cap. Soc. Euro 50.000,00 i.v.

Copyright 2023 © All rights Reserved. Design by Origami Creative Studio


Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram